{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:57Z","timestamp":1786979937366,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00277-022-04877-w","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T16:02:22Z","timestamp":1654531342000},"page":"1835-1841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study"],"prefix":"10.1007","volume":"101","author":[{"given":"Peipei","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youqian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-8859","authenticated-orcid":false,"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"4877_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fphar.2017.00019","volume":"8","author":"BL Rapoport","year":"2017","unstructured":"Rapoport BL (2017) Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front Pharmacol 8:19. https:\/\/doi.org\/10.3389\/fphar.2017.00019","journal-title":"Front Pharmacol"},{"key":"4877_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00520-016-3449-y","volume":"25","author":"LH Einhorn","year":"2017","unstructured":"Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303\u2013308. https:\/\/doi.org\/10.1007\/s00520-016-3449-y","journal-title":"Support Care Cancer"},{"key":"4877_CR3","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789","journal-title":"J Clin Oncol"},{"key":"4877_CR4","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt T, Goldschmidt H, Neben K, Freiberger A, Husing J, Gronkowski M, Thalheimer M, le Pelzl H, Mikus G, Burhenne J, Ho AD, Egerer G (2014) Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413\u20133420. https:\/\/doi.org\/10.1200\/JCO.2013.55.0095","journal-title":"J Clin Oncol"},{"key":"4877_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","volume":"105","author":"A Isoda","year":"2017","unstructured":"Isoda A, Saito R, Komatsu F, Negishi Y, Oosawa N, Ishikawa T, Miyazawa Y, Matsumoto M, Sawamura M, Manaka A (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 105:478\u2013484. https:\/\/doi.org\/10.1007\/s12185-016-2152-6","journal-title":"Int J Hematol"},{"key":"4877_CR6","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41409-020-0909-2","volume":"55","author":"N Di Renzo","year":"2020","unstructured":"Di Renzo N, Musso M, Scime R, Cupri A, Perrone T, De Risi C, Pastore D, Guarini A, Mengarelli A, Benedetti F, Mazza P, Capria V, Chiusolo P, Cupelli L, Federico V, Bozzoli V, Messa AR, Codega P, Bonizzoni E, Specchia G (2020) Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant 55:2114\u20132120. https:\/\/doi.org\/10.1038\/s41409-020-0909-2","journal-title":"Bone Marrow Transplant"},{"key":"4877_CR7","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1586\/14737140.8.11.1733","volume":"8","author":"RM Navari","year":"2008","unstructured":"Navari RM (2008) Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 8:1733\u20131742. https:\/\/doi.org\/10.1586\/14737140.8.11.1733","journal-title":"Expert Rev Anticancer Ther"},{"key":"4877_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/annonc\/mds541","volume":"24","author":"H Saito","year":"2013","unstructured":"Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2013) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24:1067\u20131073. https:\/\/doi.org\/10.1093\/annonc\/mds541","journal-title":"Ann Oncol"},{"key":"4877_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/annonc\/mdv482","volume":"27","author":"C Weinstein","year":"2016","unstructured":"Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172\u2013178. https:\/\/doi.org\/10.1093\/annonc\/mdv482","journal-title":"Ann Oncol"},{"key":"4877_CR10","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","volume":"29","author":"S Grunberg","year":"2011","unstructured":"Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2013EASE. J Clin Oncol 29:1495\u20131501. https:\/\/doi.org\/10.1200\/JCO.2010.31.7859","journal-title":"J Clin Oncol"},{"key":"4877_CR11","doi-asserted-by":"publisher","unstructured":"Zhang Z, Yang Y, Lu P, Li X, Chang J, Zheng R, Zhou L, Chen S, Chen X, Ren B, Gu W, Jiang X, Peng J, Huang M, Feng G, Shen P, Zhang Q, Zhang B, Huang Y, He J, Chen Y, Cao J, Wang H, Li W, Wan H, Nan K, Liao Z, Zhang C, Lin Z, Zhong D, Xu Q, Liu H, Sun T, Deng Y, Zhang L (2020) Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial. Ann Transl Med 8: 234. https:\/\/doi.org\/10.21037\/atm.2019.12.158","DOI":"10.21037\/atm.2019.12.158"},{"key":"4877_CR12","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.bbmt.2018.06.005","volume":"24","author":"AB Clemmons","year":"2018","unstructured":"Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24:2065\u20132071. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005","journal-title":"Biol Blood Marrow Transplant"},{"key":"4877_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"4877_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.clml.2017.06.012","volume":"17","author":"S Trifilio","year":"2017","unstructured":"Trifilio S, Welles C, Seeger K, Mehta S, Fishman M, McGowan K, Strejcek K, Eiten E, Pirotte C, Lucier E, DeFrates S, Mehta J (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk 17:584\u2013589. https:\/\/doi.org\/10.1016\/j.clml.2017.06.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4877_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/bmt.2010.205","volume":"46","author":"K Jordan","year":"2011","unstructured":"Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 46:784\u2013789. https:\/\/doi.org\/10.1038\/bmt.2010.205","journal-title":"Bone Marrow Transplant"},{"key":"4877_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000371523","volume":"89","author":"A Svanberg","year":"2015","unstructured":"Svanberg A, Birgegard G (2015) Addition of aprepitant (Emend(R)) to standard antiemetic regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting. Oncology 89:31\u201336. https:\/\/doi.org\/10.1159\/000371523","journal-title":"Oncology"},{"key":"4877_CR17","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41409-018-0106-8","volume":"53","author":"J Bubalo","year":"2018","unstructured":"Bubalo J, Mulverhill K, Meyers G, Hayes-Lattin B, Maziarz R (2018) A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 53:1010\u20131018. https:\/\/doi.org\/10.1038\/s41409-018-0106-8","journal-title":"Bone Marrow Transplant"},{"key":"4877_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/annonc\/mdl347","volume":"18","author":"SM Grunberg","year":"2007","unstructured":"Grunberg SM (2007) Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 18:233\u2013240. https:\/\/doi.org\/10.1093\/annonc\/mdl347","journal-title":"Ann Oncol"},{"key":"4877_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s10147-019-01570-3","volume":"25","author":"V Vimolchalao","year":"2020","unstructured":"Vimolchalao V, Sakdejayont S, Wongchanapai P, Sukprakun S, Angspatt P, Thawinwisan W, Chenaksara P, Sriuranpong V, Vinayanuwatikun C, Parinyanitikun N, Poovorawan N, Tanasanvimon S (2020) The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Int J Clin Oncol 25:396\u2013402. https:\/\/doi.org\/10.1007\/s10147-019-01570-3","journal-title":"Int J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04877-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04877-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04877-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:09:39Z","timestamp":1657703379000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04877-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4877"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04877-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"21 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol is in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards, and was approved by the Research Ethics Committee of The Affiliated People\u2019s Hospital of Ningbo University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Participants signed informed consent regarding publishing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}